Logo

NITO

N2OFF, Inc.

NITO

N2OFF, Inc. • NASDAQ
$3.04 ▲ 4.11% (+0.12)
Market Cap $2.90 M
52w High $122.15
52w Low $2.50
Dividend Yield 0%
P/E -0.24
Volume 3.92K
Outstanding Shares 953.03K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2K ▲ $1.179M ▼ $429K ▲ 21.45K% ▲ $0.97 ▲ $372.999K ▲
Q2-2025 $0 ▼ $2.83M ▲ $-4.509M ▼ 0% ▲ $-6.4 ▼ $-3.347M ▼
Q1-2025 $66K ▼ $671K ▼ $-1.193M ▲ -1.808K% ▼ $-2.583 ▲ $-616K ▲
Q4-2024 $140.519K ▲ $1.091M ▼ $-1.373M ▲ -976.934% ▲ $-8.4 ▲ $-1.936M ▼
Q3-2024 $9.104K $1.482M $-2.263M -24.86K% $-13.65 $-1.545M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $6.31M ▲ $11.026M ▲ $2.35M ▲ $8.93M ▲
Q2-2025 $3.409M ▲ $7.752M ▲ $2.201M ▼ $5.765M ▲
Q1-2025 $2.954M ▲ $7.365M ▲ $3.667M ▲ $3.94M ▼
Q4-2024 $2.492M ▼ $5.465M ▼ $892K ▲ $4.749M ▼
Q3-2024 $2.75M $5.822M $518.764K $5.44M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $429K ▲ $-1.073M ▼ $-351.792K ▲ $4.514M ▲ $2.907M ▲ $-1.073M ▼
Q2-2025 $-4.552M ▼ $-528K ▲ $-449K ▲ $1.402M ▼ $416K ▼ $-528K ▲
Q1-2025 $-1.257M ▲ $-809K ▼ $-1.176M ▼ $2.532M ▲ $538K ▲ $-809K ▼
Q4-2024 $-1.411M ▲ $-491.852K ▲ $-515.956K ▲ $445.968K ▲ $-563.981K ▲ $-491.852K ▲
Q3-2024 $-2.314M $-889.68K $-1.211M $392.178K $-1.717M $-889.68K

Five-Year Company Overview

Income Statement

Income Statement N2OFF looks like a very early-stage, pre‑commercial company. Over the past several years it has reported essentially no revenue and only small but recurring operating and net losses. In plain terms, the business is still in “spending mode” rather than “earning mode.” The economic engine has not yet turned on, so results reflect costs of building technology and corporate structure rather than a functioning, scaled business. Per‑share losses look very large mainly because of repeated reverse stock splits, not because the absolute dollar losses are huge.

Balance Sheet

Balance Sheet The balance sheet is extremely small and very light. Assets and equity are modest, with almost no debt, which reduces financial leverage risk but also reflects limited scale. Cash on hand appears very thin in recent years, suggesting a strong need for external funding to keep operations and R&D going. The sequence of reverse stock splits over time is a signal that the company has had to repeatedly restructure its share base, often a marker of capital pressure and a weak market valuation. Overall, the company currently has a fragile financial foundation and little buffer for setbacks.

Cash Flow

Cash Flow Cash flows mirror the income statement story: small but mostly negative operating cash flow and no meaningful capital investment yet. The business is essentially consuming cash to pay for overhead and development, without inflows from customers. Free cash flow is therefore slightly negative and entirely dependent on outside capital raises rather than internal generation. This pattern is typical of a very early-stage, R&D‑driven model, but it also means sustainability depends heavily on continued access to funding markets.

Competitive Edge

Competitive Edge N2OFF has ambitions across several attractive themes—sustainable agriculture, greenhouse gas reduction, renewable energy, and cancer therapeutics. Its strengths sit in specialized niches: eco‑friendly post‑harvest treatments, a natural solution for nitrous oxide reduction, access to European solar and storage projects via a partner, and a proprietary algorithm for targeting mitochondrial proteins in cancer. These give it pockets of differentiation through intellectual property, regulatory know‑how and technical expertise. At the same time, each of these areas is highly competitive and typically dominated by much larger, better‑funded players. The company’s tiny scale and limited financial resources make execution and commercialization a significant challenge despite the interesting technologies.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of N2OFF’s story. It is investing in green post‑harvest treatments for produce, biological tools to cut farm emissions, a project‑development model in European solar and storage, and an AI‑driven engine for discovering cancer drugs targeting mitochondrial proteins. All of these are early and largely pre‑revenue, but they address big structural trends: food waste, agricultural emissions, clean energy, and oncology. Progress will likely be measured through patents, regulatory approvals, field trial results, project milestones, and drug‑development steps rather than near‑term profits. The breadth of R&D is a double‑edged sword: it offers multiple shots on goal but also stretches a very small company across several complex domains.

Summary

N2OFF today looks less like a conventional operating company and more like a small, diversified technology platform spread across clean‑tech and biotech themes. Financially it is pre‑revenue, loss‑making, and thinly capitalized, with a history of reverse splits and reliance on external funding—factors that point to high financial fragility. Strategically, it holds a collection of differentiated technologies and partnerships that, if successfully developed and commercialized, could tap into long‑term growth areas in agriculture, emissions reduction, renewable energy and cancer treatment. The main risks center on execution, funding, regulatory and clinical uncertainty, and the complexity of managing such a broad portfolio at tiny scale. The company’s future path will depend heavily on turning its R&D and pilot projects into clear commercial traction while maintaining sufficient financial runway.

NEWS

November 18, 2025 · 9:12 AM UTC

N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination

Read more

October 30, 2025 · 9:25 AM UTC

N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers

Read more

October 23, 2025 · 8:25 AM UTC

N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Read more

September 25, 2025 · 4:01 PM UTC

N2OFF Stockholders Approve Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Read more

September 18, 2025 · 7:50 AM UTC

N2OFF Provides Business Update on Successful Execution of Solar and Energy Storage Initiatives Across Europe

Read more